Introduction
============

Chronic graft-versus-host disease (GvHD) remains an elusive disorder to characterize and represents the major cause of morbidity and mortality affecting long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT).^([@R1]-[@R4])^

Approximately 50% of patients develop chronic GvHD. The rate varies between 6% to 80% depending on several factors including recipient and donor ages, prior acute GvHD, donor type, patient/recipient gender mismatch, stem cell source, graft manipulation, use of post-transplantation donor lymphocyte infusions (DLI) and the clinical diagnosis criteria used.^([@R5]-[@R8])^ This immunologic complication after allogeneic HSCT resembles an autoimmune disease with clinical manifestations of collagen vascular diseases, such as oral ulcerations (lichen planus), keratoconjunctivitis sicca, xerostomia, polyserositis, esophagitis and stricture, vaginal ulceration and stricture, intrahepatic obstructive liver disease, obstructive pulmonary disease, scleroderma, morphea, fasciitis and myositis.^([@R2],[@R4],[@R9])^ These manifestations are associated with debilitating consequences, such as reduced quality of life, impaired functional status, need for extended immune suppression, profound chronic immune suppression leading to recurrent or life-threatening infections and death.^([@R1],[@R10]-[@R17])^

The historical classification of chronic GvHD proposed in 1980 included limited disease (i.e., only localized skin and/or liver involvement) and extensive disease (i.e., generalized skin or limited disease plus involvement of other organs).^([@R9])^ In 2001, the classification was revised to distinguish patients who required systemic immune suppression from those who did not.^([@R3])^ Although highly reproducible among transplant centers, the Seattle revised chronic GvHD criteria did not stratify patients according to outcomes.^([@R18],[@R19])^

Unlike other innovations in HSCT, progress in chronic GvHD has been slow due to the variability of the clinical manifestations of this syndrome, the lack of consistent diagnostic laboratory findings, the limited understanding of its pathogenesis and the slow accrual of patients in clinical trials.^([@R20]-[@R22])^ In the last 6 years however, the growing interest in chronic GvHD research has been spurred by the National Institute of Health (NIH) sponsored consensus project in chronic GvHD that included six working groups of multidisciplinary experts on diagnosis and staging, histopathology, biomarkers, response criteria, supportive care and design of clinical trials. Each of the six working groups presented their reports at the June 2005 NIH Consensus Meeting on critical issues for future research in chronic GvHD.^([@R20])^ Recommendations for future clinical trials by each of the NIH consensus working groups have been published based on experts\' opinion due to insufficient data at the time to provide evidence-based recommendations.^([@R23]-[@R28])^

In an effort to foster collaboration and expand the network for future clinical trials in chronic GvHD, a Brazil-Seattle consortium was established between HSCT investigators from the Fred Hutchinson Cancer Research Center (FHCRC) and from five Brazilian institutions. The current manuscript describes the establishment of the Seattle-Brazil consortium as a platform to conduct future collaborative studies in chronic GvHD and other HSCT areas and presents the results of the first 34 patients enrolled in a pilot study to determine the feasibility of conducting a multicenter, prospective, observational clinical trial in chronic GvHD using the NIH criteria^([@R23])^ in five Brazilian institutions between June 2006 and May 2009.

Methods
=======

The consortium
--------------

The Brazil-Seattle consortium was established in 2008 by a Brazilian-American expert in chronic GvHD and other late effects of HSCT at the FHCRC in Seattle and by investigators with common research interests from five Brazilian institutions (Universidade Estadual de Campinas, Instituto Nacional de Câncer in Rio de Janeiro, Universidade Federal do Rio de Janeiro, Universidade Federal do Paraná in Curitiba and Hospital Amaral Carvalho in Jaú). The objective of the consortium was to establish a platform to conduct future collaborative studies in chronic GvHD and other research areas in HSCT between investigators in Brazil and Seattle. The consortium consists of a multidisciplinary team of HSCT physicians, one dermatologist, dentists, psychiatrists, psychologists, physiotherapists and two data managers. Medical training was conducted at the FHCRC for most of the physicians and one dentist, and was extended to others members of the teams in Brazil.

The consortium held monthly teleconferences with investigators from Brazil and Seattle and met at least twice yearly during annual meetings of the American and the Brazilian Societies of HSCT and Hematology. After completion of the chronic GvHD training and translation to Portuguese of the NIH consensus criteria, a pilot study to determine the feasibility of conducting a multicenter, prospective, observational clinical trial in chronic GvHD was initiated by the consortium upon approval of the institutional review boards of each of the five participating centers.

Inclusion criteria and definitions
----------------------------------

The inclusion criteria were over 2-year-old patients with a diagnosis of chronic GvHD by NIH criteria^([@R23])^ that required systemic immunosuppression treatment and who were within the first 3 years of their allogeneic HSCT. Only patients with no evidence of primary disease relapse/progression after transplantation were included, although the presence of minimal residual disease by molecular testing was allowed. Patients with an inability to comply with study procedures or anticipated survival of less than 6 months due to co-morbid disease were excluded. The criteria for diagnosis and staging of chronic GvHD were according to the 2005 NIH consensus recommendations for clinical trials.^([@R23])^

Patients enrolled in the study within 3 months from the initial diagnosis of chronic GvHD were categorized as \'incidence cases\' and those enrolled after 3 months from the initial diagnosis of chronic GvHD were classified as \'prevalent cases\'. When patients received only topical therapy at the initial diagnosis of chronic GvHD, but subsequently required systemic treatment and then enrolled in the study, they were classified as incident or prevalent cases according to the date of the initial diagnosis of chronic GvHD and not the date when treatment with systemic immunosuppression was started.

Study procedure
---------------

No therapeutic intervention was indicated by this study. Appropriate patients were identified by individual physicians at each center at the time of clinical visits. Potentially eligible patients were approached and the study procedures outlined. Signed informed consent was required for study enrollment. The patients were registered at the local institution. They were assigned a unique sequential study identification number after verification of eligibility and receipt of informed consent. Each institution retained a file of the patients enrolled in the study.

Patients were evaluated at the time of study enrollment and at 6-month intervals. Newly diagnosed patients (incident cases) had an additional assessment 3 months after enrollment. Physicians provided standardized information about organ involvement and symptoms at each evaluation. Only enrollment data were analyzed in the pilot study.

The medical assessment included the NIH chronic GvHD diagnosis and staging consensus,^([@R20],[@R23])^ as well the Hopkins and Vienna^([@R29])^ scoring systems. Data were collected on skin, mouth, eye, gastrointestinal, liver and lung involvement, overall severity ratings (mild, moderate and severe), and perceptions of changes by physicians. As the mouth is the most common site of NIH chronic GvHD symptoms,^([@R21])^ an oral cavity diagram was included in our study ([Figure 1](#F1){ref-type="fig"}) to help to estimate the percentage of oral cavity surface involvement when grading GvHD. The length and width of the largest oral ulcer was also added to monitor response.
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Statistical analysis
--------------------

The objective of this multicenter, prospective, observational pilot study was to determine its feasibility of using the diagnosis and staging of chronic GvHD according to the NIH criteria at five institutions in Brazil. Each participating institution collected data prospectively.

Demographic and transplant related information were calculated as proportions. The comparison between groups was performed using chi-squared tests. Overall survival after onset of chronic GvHD was estimated by the Kaplan-Meier method. Analysis was carried out as of December 2009.

Results
=======

The Brazil-Seattle chronic GvHD multidisciplinary study group (GeDECH-Brasil/Seattle) was conceived by several Brazilian investigators who had been post-doctor fellows or visiting physicians at the FHCRC and by Mary Flowers, a collaborator and mentor in Seattle. The first initiative of the GeDECH-Brasil-Seattle consortium was to conduct a feasibility, multicenter, prospective, observational pilot study in a chronic GvHD Brazilian population applying NIH criteria similar to those being tested in a larger multicenter observational chronic GvHD study in the United States by Stephanie Lee et al. since 2007.

A total of 34 patients were enrolled in this pilot study. At least 5 patients were enrolled from each of the five participating institutions with the first patient enrolled in March 2008 and the last one in September 2009.

Patient and transplant characteristics are shown in [Table 1](#T1){ref-type="table"}. The median patient age was 36 years old (range: 15 - 65 years) and 67% (n = 23) were male. The majority of patients (94%) had HLA matched related donors (n=32) and most (91%) received a high-dose pre-transplant conditioning regimen with chemotherapy but without total body irradiation (n = 31). The source of stem cells for the HSCT was peripheral blood in 21 patients (64%). Twenty patients (59%) received their first allogeneic HSCT between 2008 and 2009 and 14 patients (41%) between 2006 and 2007.

###### 

Patient and transplant characteristics

  ----------------------------------------------------------------- ------------
  Characteristic                                                    n = 34
  Patient age, median (range) years                                 36 (15-65)
  Male patients no. (%)                                             23 (67)
  Diagnosis at transplant, no. (%)                                  
      Acute leukemia                                                16(47)
      Chronic myeloid leukemia                                      9(26)
      Myelodysplasia syndrome                                       3(9)
      Non malignant disorders                                       3(9)
      Others                                                        3(9)
  Donor age, median (range), years                                  38 (4-58)
  Donor/recipient gender, no. (%)                                   
      Female / male                                                 9(26)
      Other                                                         25 (74)
  Donor type, no. (%)                                               
      HLA-identical related                                         32 (94)
      HLA-mismatched related                                        1(3)
      HLA-mismatched unrelated                                      1(3)
  High dose conditioning regimen, no. (%) yes                       31 (91)
  Conditioning regimen types, no. (%)                               
      High dose busulfan and cyclophosphamide                       22 (64)
      High dose busulfan and fludarabine                            4(12)
      High dose cyclophosphamide and total body irradiation (TBI)   2(6)
      High dose - others                                            3(9)
      Reduced dose: fludarabine and TBI                             3(9)
  Source of stem cells, no. (%)                                     
      Bone marrow                                                   13 (38%)
      Mobilized blood                                               21 (62)
  GvHD prophylaxis, no. (%)                                         
      Cyclosporine + methotrexate                                   25 (73)
      Methotrexate                                                  5(15)
      Cyclosporine + methotrexate + steroids                        1 (3)
      Cyclosporine + mycophenolate mofetil                          3(9)
  Year of transplantation, no. (%)                                  
      2006                                                          3(9)
      2007                                                          11(32)
      2008                                                          18(53)
      2009                                                          2(6)
  Prior grade 2-4 acute GvHD, no. (%)                               13 (38)
  ----------------------------------------------------------------- ------------

Chronic GvHD characteristics are shown in [Table 2](#T2){ref-type="table"}. The median time from HSCT to diagnosis of chronic GvHD was 5.9 months (range: 3 - 16 months) and from initial diagnosis of chronic GvHD to enrollment was 2.2 months (range: 0.4 - 15 months).

###### 

Chronic GvHD characteristics

  ------------------------------------------------------------------ --------------
  Characteristic                                                     n = 34
  Months from transplant to chronic GvHD, median (range)             5.9 (3-16)
  Months from chronic GvHD to enrollment, median (range)             2.2 (0.4-15)
  Chronic GvHD subcategories, no. (%)                                
      Overlap                                                        26 (76)
      Classic                                                        8(24)
  Months from transplant to chronic GvHD, median (range)             
      Overlap                                                        5.9 (3-10)
      Classic                                                        7.3 (3-16)
  Type of onset, no. (%)                                             
      De novo                                                        21 (62)
      Quiescent                                                      6(18)
      Progressive                                                    7(20)
  High risk features at initial diagnosis of chronic GvHD, no. (%)   
      Platelet count \< 100.000 / mL                                 5(15)
      Skin involved by \> 50% of total body surface area (BSA)       10(29)
      Corticosteroids dose ≥ 0.5 mg/kg/day                           17(50)
  No. of sites involved at enrollment, no. (%)                       
      1                                                              4(12)
      2                                                              11 (32)
      3                                                              11 (32)
      ≥4                                                             8(24)
  YGvHD severity at enrollment, no. (%)                              
      Moderate                                                       21 (62)
      Severe                                                         13 (38)
  ------------------------------------------------------------------ --------------

Of the 34 patients, 24 (71%) were incident cases and 10 (29%) prevalent cases. Twenty-six (76%) patients met the NIH chronic GvHD subcategory of overlap syndrome and 8 (24%) the classic subcategory. The median time from transplant to chronic GvHD was shorter for overlap syndrome at 5.9 months (range: 3 - 10 months) compared to 7.3 months (range: 3 - 16 months) for the classic subcategory. Among the 34 patients, 4 (12%) had one organ/site involvement, 11 (32%) had two organ/site involvement, 11 (32%) had three organ/site involvement and 8 (24%) had four or more organ/ site involvement at the time of study enrollment. The organs/sites involved by chronic GvHD at initial diagnosis are shown in [Figure 2](#F2){ref-type="fig"}.
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Overall, 21/34 (62%) patients had no prior history of grade 2-4 acute GvHD with 5 of 8 (62%) in the classic and 16 of 26 (47%) in overlap chronic GvHD subcategories. Of the 13/34 (38%) patients with prior grade 2-4 acute GvHD, 10/26 (38%) belonged to the overlap chronic GvHD subcategory and 3/8 (38%) to the classic subtype. The distribution of patients with and without prior acute GvHD was not statistically significant between the chronic GvHD subcategories.

Most patients (21/34; 62%) had *de novo* onset of chronic GvHD, 15 in the overlap and 6 in the classic subcategories. No statistically significant differences between type of onset and NIH chronic GvHD subcategories were found (p-value = 0.17) ([Figure 3](#F3){ref-type="fig"}).
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The frequency of selected high risk features at the time of initial diagnosis of chronic GvHD associated with poor survival or prolonged immunosuppression^([@R1],[@R5],[@R17],[@R28])^ are shown in [Table 2](#T2){ref-type="table"}. At the time of initial diagnosis, 7 patients (20%) had progressive onset of chronic GvHD, 5 patients (15%) had platelet counts below 100 x 10^9^/L, 10 patients (29%) had skin involvement of more than 50% of the total body surface area and 17 patients (50%) were receiving corticosteroids at a dose equal to or greater than 0.5 mg/kg/day.

The severity of chronic GvHD in the cohort studied is shown in [Figure 4](#F4){ref-type="fig"}. Overall, the severity of chronic GvHD was graded as moderate in 21/34 (62%) and severe in 13/34 (38%) patients. Among the 21 patients with moderate disease, 16 were in the overlap and 5 in the classic chronic GvHD subcategories. Of the 13 patients with severe disease, 10 were in the overlap and 3 in the classic chronic GvHD groups. There was no significant statistical difference between moderate and severe disease between the subcategories (p-value = 0.64).
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After a median follow-up of 16.5 months, the overall survival from the initial chronic GvHD diagnosis in our patient population was 75% ([Figure 5](#F5){ref-type="fig"}).
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Discussion
==========

Two points should be highlighted in this paper. The first relates to describing the establishment of a consortium between investigators at the FHCRC and at Brazilian institutions to promote collaboration in research areas of common interest in HSCT, such as the Brazil-Seattle chronic GvHD multidisciplinary study group. The second relates to reporting the feasibility of conducting a multicenter pilot observational study in chronic GvHD applying the diagnostic, staging and response criteria as recommended by the 2005 NIH consensus conference for clinical trials.

In this pilot study we describe the characteristics of patients with NIH defined chronic GvHD who met the overlap syndrome and classic subcategories. The most prevalent subcategory of chronic GvHD observed was the overlap syndrome (76%), a result similar to that reported in a large North American retrospective study^([@R30])^ but different to others reports.^([@R31]-[@R33])^ Most patients in our study had *de novo* onset of chronic GvHD (i.e., no prior acute GvHD) equally distributed among patients in the overlap and classic chronic GvHD subcategories. The majority of patients had 2 or 3 organs/sites involved with the mouth being the most prevalent site (91%), thus corroborating with previous findings.^([@R21])^ Similar to other studies,^([@R31],[@R32])^ the overall severity of chronic GvHD of most patients in our study cohort was moderate in both overlap syndrome and classic chronic GvHD subcategories.

Presence of high risks features associated with poor survival at the initial diagnosis of chronic GvHD (i.e., thrombocytopenia, progressive onset of chronic GvHD and skin involvement of more than 50% of the body surface area) was observed in approximately one third of patients in our study. While the follow-up is short, the 75% overall survival is an encouraging observation.

Several retrospective studies on evaluating the NIH criteria by assessing outcomes among patients with historically defined chronic GvHD reported conflicting results.^([@R30]-[@R35])^ In a large retrospective study evaluating the NIH consensus criteria in the classification of late acute and chronic GvHD, Vigorito et al.^([@R30])^ reported that antecedent late acute GvHD was associated with an increased risk of nonrelapse mortality and prolonged treatment in patients with NIH chronic GvHD. In that study, however, there was no statistically significant association between the presence or absence of NIH chronic GvHD criteria with survival, risk factors or non-relapse mortality, recurrent malignancy, or duration of systemic treatment.^([@R30])^ In two smaller studies, however, Jagasia et al.^([@R31])^ and Arora et al.^([@R32])^ reported lower survival among patients with NIH GvHD defined as late, persistent, recurrent and acute compared to patients in overlap syndrome or classic chronic GvHD subcategories. In another study evaluating the NIH GvHD criteria, Cho et al.^([@R33])^ reported no significant differences in GvHD-specific survival according to the NIH GvHD diagnostic criteria. Pérez-Simón et al.,^([@R34])^ Kim et al.^([@R35])^ and other investigators^([@R32],[@R33])^ evaluated the overall severity of chronic GvHD according to NIH criteria as a risk factor for survival and non-relapsed mortality and reported a lower survival for patients graded as severe.

The discrepant results of the above studies may be explained by differences in the historical criteria used to make the diagnosis of chronic GvHD and by inadequacies in documenting the presence or absence of the diagnostic and distinctive manifestations of chronic GvHD necessary to categorize patients by the NIH consensus criteria. Considering the previously inconsistent results^([@R30]-[@R35])^ and that late acute GvHD by NIH criteria represents a subcategory of the historical chronic GvHD diagnosis,^([@R3],[@R23])^ with proper stratification, patients with late acute GvHD should be included in clinical trials for chronic GvHD. When analyzing chronic GvHD as an outcome of HSCT, the capture of both late acute and chronic GvHD by the 2005 NIH criteria is important, since failing to do so will likely underestimate the incidence of chronic GvHD and lead to misinterpretation of results when this outcome is compared with prior studies using the historical chronic GvHD criteria.^([@R3],[@R23])^

In conclusion, this pilot study demonstrates the feasibility of applying the NIH consensus criteria for the diagnosis and scoring of chronic GvHD in a multicenter prospective study at five Brazilian institutions and, more importantly, in establishing a consortium of investigators interested in new opportunities to collaborate in future intervention, validation, and biomarker clinical trials in chronic GvHD and other areas of common research interest in hematopoietic stem cell transplantation.

The authors thank Kate Chilson for her assistance in the study forms and particularly to all patients who participated in the study.

Conflict-of-interest disclosure: The authors declare no competing financial interest
